phrykt

Eikon Therapeutics, Inc. (EIKN): who owns it and who trades it

As of Nov 16, 2026, EIKN insiders reported 7 purchases worth $44.7M in the last 12 months. The largest buyer was Column Group Opportunity III, LP (10% owner), with $38.1M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Eikon Therapeutics

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns EIKN

77 funds and institutions reported EIKN shares worth $347M at the end of Q2 2026, about 49% of the company. The largest holder is FMR LLC (Fidelity) with 9.2%.

Funds and institutions (13F) 49%Everyone else 51%

10 largest owners, by share of the company

FMR LLC (Fidelity)9.2%
BlackRock, Inc.7.9%
Foresite Capital Management IV, LLC3.6%
Merck & Co., Inc.3.1%
T. Rowe Price Investment Management, Inc.2.9%
Foresite Capital Management V, LLC2.4%
Capital World Investors2.2%
T. Rowe Price Associates1.9%
Vanguard Capital Management LLC1.7%
EcoR1 Capital, LLC1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)4.99M9.22%$65.2M+30%
BlackRock, Inc.4.28M7.91%$55.9M+29%
Foresite Capital Management IV, LLC1.94M3.59%$25.4MNo change
Merck & Co., Inc.1.67M3.08%$21.7MNo change
T. Rowe Price Investment Management, Inc.1.60M2.95%$20.8M+30%
Foresite Capital Management V, LLC1.32M2.44%$17.2MNo change
Capital World Investors1.18M2.17%$15.3M+3%
T. Rowe Price Associates1.01M1.86%$13.1M+3%
Vanguard Capital Management LLC922,7071.70%$12M-5%
EcoR1 Capital, LLC732,6061.35%$9.6MNo change
Alliancebernstein L.P.641,8881.19%$6.8M-37%
Geode Capital Management, LLC556,9551.03%$7.3M+103%
Baker Bros. Advisors LP555,5551.03%$7.2MNo change
Soros Capital Management LLC484,6720.90%$6.3MNo change
StepStone Group LP395,3400.73%$5.2MNo change
Canada Pension Plan Investment Board379,0240.70%$4.9MNo change
State Street Corp354,0930.65%$4.6M+782%
Franklin Resources Inc350,0000.65%$4.6MNo change
General Catalyst Group Management, LLC305,2330.56%$4MNo change
UBS Group AG263,9320.49%$3.4M+166%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, EIKN insiders reported $44.7M of open-market purchases and $0 of sales.

Purchases, 12 months
$44.7M
7 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 3, 2026
Filed Sep 8, 2026

Purchases and sales by month

$43.6M$43.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 3, 2026Tim Kutzkey +710% ownerPurchase89,200$11.56$1MForm 4
Feb 6, 2026Column Group Opportunity III, LP +710% ownerPurchase630,881$18.00$11.4MForm 4
Feb 6, 2026Column Group Opportunity III, LP +710% ownerPurchase49,556$18.00$892KForm 4
Feb 6, 2026Column Group Opportunity III, LP +710% ownerPurchase1.44M$18.00$25.9MForm 4
Feb 4, 2026Foresite Capital Opportunity Management V, LLC +710% ownerPurchase55,555$18.00$1000KForm 4
Feb 4, 2026Kenneth C FrazierDirectorPurchase111,111$18.00$2MForm 4
Feb 4, 2026Josh WolfeDirectorPurchase138,888$18.00$2.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Column Group Opportunity III, LP10% owner$38.1M–Feb 6, 2026
Josh WolfeDirector, 10% owner$2.5M–Feb 4, 2026
Kenneth C FrazierDirector$2M–Feb 4, 2026
Tim Kutzkey10% owner$1M–Sep 3, 2026
Foresite Capital Opportunity Management V, LLC10% owner$1000K–Feb 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EIKN short interest

High short interest. 10.2% of EIKN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 53%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.54M EIKN shares were sold short, 10.2% of the shares outstanding, down 13.1% from the report before. At the average daily volume of 528,963 shares, buying them all back would take about 10.5 trading days (days to cover).

Shares short, % of all shares

10.2%May 15Oct 3012.5%

Days to cover

10.5May 15Oct 3021.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.54M10.22%-13%528,96310.5
Oct 15, 20266.37M11.76%+1%545,15211.7
Sep 30, 20266.29M11.62%+15%716,0528.8
Sep 15, 20265.45M10.07%+3%588,7969.3
Aug 31, 20265.28M9.75%+26%512,72010.3
Aug 14, 20264.18M7.72%-14%427,1879.8
Jul 31, 20264.88M9.01%+5%244,28820.0
Jul 15, 20264.63M8.55%-0%403,38711.5
Jun 30, 20264.63M8.55%+3%584,2457.9
Jun 15, 20264.50M8.32%+11%237,86818.9
May 29, 20264.07M7.51%+13%392,91410.3
May 15, 20263.61M6.67%+7%347,17210.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Eikon Therapeutics company events

Eikon Therapeutics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 12, 2026.

  1. Nov 12, 2026ResultsReleased financial results. Filing
  2. Oct 26, 2026AnnouncementThe Company presented updated data from its TeLuRide-005 trial of EIK1001 at the 2026 ESMO Congress, detailed below. Filing
  3. Oct 23, 2026AnnouncementThe Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress, detailed below. Filing
  4. Aug 14, 2026AnnouncementShared information with investors. Filing
  5. Aug 13, 2026ResultsReleased financial results. Filing
  6. Aug 3, 2026LeadershipLeon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. Filing
  7. Jun 10, 2026LeadershipThe Board of Directors of Eikon Therapeutics, Inc. appointed Ma. Filing
  8. Jun 1, 2026AnnouncementThe Company issued a press release announcing updated data on its Phase 2 trial of EIK1001 in first-line patients with stage 4 non-small cell lung cancer and new and updated data on its Phase 1/2 trial of EIK1003 in patients with advanced solid tumors, which were presented at the 2026 American… Filing
  9. May 11, 2026ResultsReleased financial results. Filing
  10. Mar 30, 2026ResultsReleased financial results. Filing
  11. Feb 6, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold EIKN

3 of the 50 well-known investors we track reported holding EIKN in their latest 13F filing. The largest position is Israel Englander's, worth $3.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026419,095$3.4M0.0%+215%
Ken Griffin · Citadel AdvisorsQ3 2026354,016$2.8M0.0%+2618%
Paul Tudor Jones · Tudor Investment CorpQ3 202615,000$121K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named EIKN in the last 120 days.

FiledHolderFormStake
Oct 7, 2026FMR LLC13G/A10.2%
Oct 7, 2026FMR LLC13G/A10.2%
Oct 2, 2026Abu Dhabi Investment Authority13G/A2.1%
Oct 2, 2026Abu Dhabi Investment Authority13G/A2.1%

Questions about Eikon Therapeutics, Inc. (EIKN) stock

Who owns the most EIKN stock?

The largest reported owner of Eikon Therapeutics, Inc. (EIKN) is FMR LLC (Fidelity), with 9.2% of the company. In total, 77 funds and institutions reported holding EIKN at the end of Q2 2026, together about 49% of the shares. See the largest owners.

Are EIKN insiders buying or selling?

In the last 12 months, EIKN insiders reported 7 open-market purchases worth $44.7M and no sales. The latest trade was on Sep 3, 2026. See every trade.

What is the short interest in EIKN?

As of Oct 30, 2026, 5.54M EIKN shares were sold short, 10.2% of the shares outstanding, down 13.1% from the report before. At the average daily volume of 528,963 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.

Which famous investors hold EIKN?

3 of the 50 well-known investors we track reported EIKN in their latest 13F filing, including Israel Englander, Ken Griffin, Paul Tudor Jones. The largest position is worth $3.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.